Professor Brendan McAdam:

We know from ESC guidelines that we are told to get people with heart disease and bad cholesterol down to less than 1.4 mmol/L. Between 30% and 40% of patients actually achieve that target, which means there is a huge residual risk of patients not being treated properly. As was mentioned in the report, we are the lowest prescribers of these injectable cholesterol medications in Europe, which is very disappointing and very bad for our patients.